GLP1R and polycystic ovary syndrome: Glucagon-like peptide-1 (GLP-1) receptor agonists and other anti-obesity pharmacotherapies are widely acknowledged as supplementary alternatives for weight management in women with polycystic ovarian syndrome (PCOS) when lifestyle modifications prove inadequate.